CY1106899T1 - Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα - Google Patents

Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα

Info

Publication number
CY1106899T1
CY1106899T1 CY20071101254T CY071101254T CY1106899T1 CY 1106899 T1 CY1106899 T1 CY 1106899T1 CY 20071101254 T CY20071101254 T CY 20071101254T CY 071101254 T CY071101254 T CY 071101254T CY 1106899 T1 CY1106899 T1 CY 1106899T1
Authority
CY
Cyprus
Prior art keywords
peptide
amyloid peptide
group
compounds
amino
Prior art date
Application number
CY20071101254T
Other languages
English (en)
Inventor
Mark A Findeis
Kathryn Phillips
Gary L Olson
Christopher Self
Original Assignee
Praecis Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharmaceuticals Incorporated filed Critical Praecis Pharmaceuticals Incorporated
Publication of CY1106899T1 publication Critical patent/CY1106899T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχονται ενώσεις που διαμορφώνουν την συσσωμάτωση φυσικών β-αμυλοειδών πεπτιδίων. Οι διαμορφωτές της εφεύρεσης περιλαμβάνουν πεπτίδιο, κατά προτίμηση βασιζόμενο σε β-αμυλοειδές πεπτίδιο, που αποτελείται εξ ολοκλήρου από D-αμινοξέα. Κατά προτίμηση το πεπτίδιο περιλαμβάνει 3-5 υπολείμματα D-αμινοξέων και περιλαμβάνει τουλάχιστον δύο υπολείμματα D-αμινοξέων που επιλέγονται χωριστά από την ομάδα που αποτελείται από D-λευκίνη, D-φαινυλαλανίνη και D-βαλίνη. Σε ιδιαίτερα προτιμητέα υλοποίηση, το πεπτίδιο είναι οπισθοανάστροφο ισομερές β-αμυλοειδούς πεπτιδίου, κατά προτίμηση οπισθοανάστροφο ισομερές του Αβ17-21.· Σε ορισμένες υλοποιήσεις, το πεπτίδιο τροποποιείται στο αμινοτελικό άκρο, στο καρβοξυτελικό άκρο, ή και στα δύο. Οι προτιμητέες αμινοτελικές τροποποιητικές ομάδες περιλαμβάνουν αλκυλομάδες. Οι προτιμητέες καρβοξυτελικές τροποποιητικές ομάδες περιλαμβάνουν ομάδα αμιδίου, ομάδα οξικού, ομάδα αλκυλικού αμιδίου, ομάδα αρυλικού αμιδίου ή υδροξυ-ομάδα. Αποκαλύπτονται επίσης φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ενώσεις της εφεύρεσης, και μέθοδοι διάγνωσης και θεραπευτικής αγωγής για αμυλοειδογόνες ασθένειες χρησιμοποιώντας τις ενώσεις της εφεύρεσης.
CY20071101254T 1999-03-04 2007-10-02 Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα CY1106899T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12273699P 1999-03-04 1999-03-04
EP00916028A EP1161449B1 (en) 1999-03-04 2000-03-03 Modulators of beta-amyloid peptide aggregation comprising d-amino acids

Publications (1)

Publication Number Publication Date
CY1106899T1 true CY1106899T1 (el) 2012-09-26

Family

ID=22404455

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101254T CY1106899T1 (el) 1999-03-04 2007-10-02 Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα

Country Status (19)

Country Link
US (3) US6610658B1 (el)
EP (1) EP1161449B1 (el)
JP (2) JP2002543043A (el)
KR (1) KR100771712B1 (el)
CN (1) CN1279053C (el)
AT (1) ATE366259T1 (el)
AU (1) AU781292B2 (el)
BR (1) BR0008738A (el)
CA (1) CA2362834C (el)
CY (1) CY1106899T1 (el)
DE (1) DE60035412T2 (el)
DK (1) DK1161449T3 (el)
ES (1) ES2290023T3 (el)
HK (1) HK1040722B (el)
NZ (1) NZ514414A (el)
PT (1) PT1161449E (el)
RU (1) RU2260599C2 (el)
WO (1) WO2000052048A1 (el)
ZA (1) ZA200107913B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277826B1 (en) * 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
ATE366259T1 (de) * 1999-03-04 2007-07-15 Praecis Pharm Inc Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
GB9917725D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
JP2003522152A (ja) * 2000-02-11 2003-07-22 プラエシス ファーマシューティカルズ インコーポレーテッド 薬物の生物学的利用能を高める方法
AUPR215700A0 (en) * 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
DE10117281A1 (de) * 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
US8330026B2 (en) 2002-04-18 2012-12-11 Yeda Research and Development Co., Ltd., Weizmann Institute of Science Derivatives of the NF-κB inducing enzyme, their preparation and use
CA2511606A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CN100340599C (zh) * 2003-06-09 2007-10-03 湖南大学 多聚赖氨酸淀粉纳米颗粒与制备方法及作为基因载体的应用
GB0503434D0 (en) * 2005-02-18 2005-03-30 Senexis Ltd Amyloid-binding peptides, analogues and uses thereof
EP2377886A1 (en) * 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antibody glycosylation in the variable region
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
KR101842076B1 (ko) * 2009-12-07 2018-03-27 피어이스 파마슈티컬즈 게엠베하 주어진 표적에 대한 친화성을 갖는 인간의 리포칼린 2의 뮤테인
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
CA2885680C (en) 2011-09-07 2022-10-04 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal.
KR101437354B1 (ko) * 2012-07-27 2014-09-05 한국과학기술연구원 고수율 및 고순도의 아밀로이드-베타 펩타이드의 제조방법
KR20230128606A (ko) * 2022-02-28 2023-09-05 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR82516E (fr) * 1962-10-11 1964-02-28 Ciba Geigy Procédé de préparation de dérivés peptidiques, notamment d'hydrazides peptidiques
US4119493A (en) 1975-10-23 1978-10-10 (Zaidanhojin) Sagami Chemical Research Center Process for producing a peptide
US5284664A (en) 1988-08-04 1994-02-08 Kremers-Urban Company Method of treating the symptoms of Alzheimer's disease
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5338663A (en) 1990-08-24 1994-08-16 President And Fellows Of Harvard College Method of identifying inhibitors of β-protein esterase activity
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5338837A (en) 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6120768A (en) 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
AU7043894A (en) 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
US5541290A (en) 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
CA2125467C (en) 1993-07-06 2001-02-06 Heinz Dobeli Process for producing hydrophobic polypeptides, proteins or peptides
AU7556994A (en) 1993-08-13 1995-03-14 Molecular Geriatrics Corporation Methods for the diagnosis of alzheimer's disease
GB9317120D0 (en) 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
JPH07149668A (ja) 1993-11-30 1995-06-13 Kanegafuchi Chem Ind Co Ltd アミロイド沈着検出用物質
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
ES2175083T3 (es) * 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5767233A (en) 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
US6277826B1 (en) * 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1997021728A1 (en) * 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
EP1586584A1 (en) * 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
ATE366259T1 (de) * 1999-03-04 2007-07-15 Praecis Pharm Inc Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren

Also Published As

Publication number Publication date
EP1161449B1 (en) 2007-07-04
PT1161449E (pt) 2007-10-12
CN1279053C (zh) 2006-10-11
CN1362967A (zh) 2002-08-07
ES2290023T3 (es) 2008-02-16
US20050137128A1 (en) 2005-06-23
US6610658B1 (en) 2003-08-26
NZ514414A (en) 2004-02-27
DE60035412D1 (de) 2007-08-16
JP2002543043A (ja) 2002-12-17
CA2362834A1 (en) 2000-09-08
US7803774B2 (en) 2010-09-28
AU781292B2 (en) 2005-05-12
BR0008738A (pt) 2001-12-26
CA2362834C (en) 2005-12-06
ZA200107913B (en) 2002-11-27
AU3719600A (en) 2000-09-21
EP1161449A1 (en) 2001-12-12
KR20020007316A (ko) 2002-01-26
US20030236197A1 (en) 2003-12-25
ATE366259T1 (de) 2007-07-15
US6831066B2 (en) 2004-12-14
HK1040722B (zh) 2008-02-22
KR100771712B1 (ko) 2007-10-30
HK1040722A1 (en) 2002-06-21
RU2260599C2 (ru) 2005-09-20
DK1161449T3 (da) 2007-11-05
JP2011121952A (ja) 2011-06-23
WO2000052048A9 (en) 2002-04-11
WO2000052048A1 (en) 2000-09-08
DE60035412T2 (de) 2008-02-14

Similar Documents

Publication Publication Date Title
CY1106899T1 (el) Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα
HK1021741A1 (en) Modulators of beta-amyloid peptide aggregation comprising d-amino acids
DK1521774T3 (da) Trunkerede Tau-proteiner
EP2036924A3 (en) Gene regulatory peptides
AR023208A1 (es) Nutraceuticos con 1-metil ester de n-[n-3,3-dimetilbutil)-l-alfa-aspartil]-l-fenilalanina
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE69635493D1 (de) Verfahren zur herstellung von l-aminosäuren
DE69822176D1 (de) Peptid/lipid-komplexbildung durch co-lyophilisation
DE69526216D1 (de) Antifungaleverfahren und mitteln
DE69934813D1 (de) Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
WO2005060683A3 (en) Small peptides for the treatment of alzheimer’s disease and other beta-amyloid protein fibrillogenesis disorders
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
DE59810043D1 (de) Verfahren zur Herstellung eines pharmazeutisch aktiven Peptides
ATE245433T1 (de) Verwendung von lipopeptiden oder lipoproteinen zur wundbehandlung
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
EP1870419A3 (en) Modulators of beta-amyloid peptide aggregation comprising d-amino acids
DE69413637D1 (de) Verwendung von verzweigtkettigen Aminosäuren zur Herstellung eines Arzneimittels zur Behandlung von tardiver Dyskinesia
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
EP1418807B8 (en) A method of inducing the formation of neurofibrillary tangles in transgenic animals
DE59915086D1 (de) Rekombinante l-n-carbamoylase aus arthrobacter aurescens, verfahren zur herstellung von l-aminosäuren mittels dieser
HUP9601528A2 (hu) Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények